

# Medicare Medical Policy

## Spinal Stabilization Devices and Interspinous Spacers

MEDICARE MEDICAL POLICY NUMBER: 392

<b>Effective Date:</b> 6/1/2026	MEDICARE COVERAGE CRITERIA .....	2
<b>Last Review Date:</b> 5/2026	POLICY CROSS REFERENCES.....	3
<b>Next Annual Review:</b> 5/2027	POLICY GUIDELINES.....	3
	REGULATORY STATUS.....	5
	BILLING GUIDELINES AND CODING .....	6
	REFERENCES.....	7
	POLICY REVISION HISTORY.....	8

**INSTRUCTIONS FOR USE:** Company Medicare Medical Policies serve as guidance for the administration of plan benefits and do not constitute medical advice nor a guarantee of coverage. Company Medicare Medical Policies are reviewed annually to guide the coverage or non-coverage decision-making process for services or procedures in accordance with member benefit contracts (otherwise known as Evidence of Coverage or EOCs) and Centers of Medicare and Medicaid Services (CMS) policies, manuals, and other CMS rules and regulations. In the absence of a CMS coverage determination or specific regulation for a requested service, item or procedure, Company policy criteria or applicable utilization management vendor criteria may be applied. These are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.

The Company reserves the right to determine the application of Medicare Medical Policies and make revisions to these policies at any time. Any conflict or variance between the EOC and Company Medical Policy will be resolved in favor of the EOC.

**SCOPE:** Providence Health Plan, Providence Health Assurance, and Providence Plan Partners as applicable (referred to individually as “Company” and collectively as “Companies”).

# PRODUCT AND BENEFIT APPLICATION

Medicare Only

## MEDICARE COVERAGE CRITERIA

**IMPORTANT NOTE:** More than one Centers for Medicare and Medicaid Services (CMS) reference may apply to the same health care service, such as when more than one coverage policy is available (e.g., both an NCD and LCD exist). All references listed should be considered for coverage decision-making. The Company uses the most current version of a Medicare reference available at the time of publication; however, these websites are not maintained by the Company, so Medicare references and their corresponding hyperlinks may change at any time. If there is a conflict between the Company Medicare Medical Policy and CMS guidance, the CMS guidance will govern.

**Note:** The plan has many policies regarding surgical procedures and devices used for spinal care. For example, the iFuse Implant System™ for sacroiliac joint fusion is addressed in the separate Medicare medical policy, [Back: Sacroiliac Joint Fusion or Stabilization](#). Please see the health plan’s list of medical policies to find the applicable spinal procedure policy.

Service	Medicare Guidelines
	<p><b>Medicare Coverage Criteria:</b> “MA organizations may create publicly accessible internal coverage criteria... when coverage criteria are not fully established in applicable Medicare statutes, regulations, NCDs or LCDs.” (§ 422.101(b)(6) – see <a href="#">Policy Guidelines</a> below)</p> <ul style="list-style-type: none"> <li>• <b>Medicare Coverage Manuals:</b> Medicare does not have criteria for interspinous process decompression (IPD), also referred to as spinal stabilization devices or interspinous spacers in a coverage manual.</li> <li>• <b>National Coverage Determination (NCD):</b> Medicare does not have a national coverage policy for IPD, spinal stabilization devices or interspinous spacers.</li> <li>• <b>Noridian J-F Local Coverage Determination (LCD)/Local Coverage Article (LCA):</b> As of the most recent policy review, no Medicare contractor (MAC) has an <i>active</i> LCD to address IPD, spinal stabilization devices or interspinous spacers, including the designated MAC for the plan’s service area.</li> <li>• Therefore, in the absence of established Medicare coverage criteria in a manual, NCD, LCD, or other regulatory guidance for the health plan’s service area, Company criteria below are applied for medical necessity decision-making. In this case, Medicare coverage criteria are considered “not fully established” as defined under CFR § 422.101(6)(i)(C) as there is no Medicare coverage criteria available.</li> <li>• <b>NOTE:</b> <i>The summary of evidence, as well as the list of citations/references used in the development of the Company’s internal coverage criteria, are publicly available and can be found using the Company medical policy link below [CFR § 422.101(6)(ii)(A) and (B)].</i></li> </ul>
<p>Spinal Stabilization Devices and Interspinous Spacers</p>	<p>Company medical policy for <a href="#">Spinal Stabilization Devices and Interspinous Spacers</a></p>

- |  |  |
|--|--|
|  | I. These services are considered <b>not medically necessary</b> for Medicare plan members based on the Company medical policy. <u>See Policy Guidelines below.</u> |
|--|--|

**IMPORTANT NOTICE:** While some services or items may appear medically indicated for an individual, they may also be a direct exclusion of Medicare or the member's benefit plan. Such excluded services or items by Medicare and member EOCs include, but are not limited to, services or procedures considered to be cosmetic, not medical in nature, or those considered not medically reasonable or necessary under *Title XVIII of the Social Security Act, §1862(a)(1)(A)*. If there is uncertainty regarding coverage of a service or item, please review the member EOC or submit a pre-service organization determination request. Note that the Medicare Advance Beneficiary Notice of Noncoverage (ABN) form **cannot** be used for Medicare Advantage members. (*Medicare Advance Written Notices of Non-coverage. MLN006266 May 2021*)

## POLICY CROSS REFERENCES

- [Back: Sacroiliac Joint Fusion or Stabilization](#), MP379

The full Company portfolio of Medicare Medical Policies is available online and can be [accessed here](#).

## POLICY GUIDELINES

### BACKGROUND

#### Dynamic Stabilization Devices

Dynamic stabilization devices provide an adjunct or alternative to spinal fusion for the treatment of chronic instabilities or deformities of the thoracic, lumbar, and sacral spine, including, but not limited to, degenerative spondylolisthesis or previous failed spinal fusion. In contrast to rigid devices that fully stabilize affected spinal segments, dynamic stabilization devices use flexible materials – anchored to the vertebrae by either synthetic cords or pedicle screws – which purport to preserve some measure of mobility of the spinal segment while also stabilizing the joint. Examples of dynamic stabilization devices include, but may not be limited to, the following:

- Aspen Spinous Fixation System
- AccuFlex™ System
- BioFlex System
- Bronsard's Ligament
- CD Horizon Agile™ Dynamic Stabilization Devices
- CD Horizon Spire Fixation System
- Cosmic™ Posterior Dynamic System
- DSS Stabilization
- DSS (Dynamic Soft Stabilization) System
- DTO (Dynesys-to-Optima)
- Dynabolt™ Dynamic Stabilization System
- Dynesys®
- Expedium™
- FASS (Fulcrum Assisted Soft Stabilization)
- Graf Ligament

- IsoBar® Spinal System
- Leeds-Keio Ligamentoplasty
- LemiFlex Spinal Stabilization
- NFix™ II Dynamic Stabilization
- NFlex™ Controlled Motion System
- REVERE Stabilization System
- Satellite™ Spinal System
- Stabilimax NZ Dynamic Spine Stabilization System
- TRANSITION® Stabilization System
- Viper™
- Zodiac DynaMo System

### Interspinous Spacers

Interspinous spacers are small devices, implanted between vertebral spinous processes at one or two vertebral levels, that stabilize or distract adjacent lamina and/or spinous processes. The spacers are thought to alleviate pain in patients with spinal stenosis and neurogenic claudication by expanding the neural foramen, decompressing the nerves and limiting painful lumbar extension, while maintaining the flexion of the spinal interspace. Examples of interspinous spacers include, but may not be limited to, the following:

- Aperius™ - PerCLID™ System
- Coflex® Interlaminar Stabilization Device
- DIAM™ Spinal Stabilization System
- Falena® Interspinous Decompression Device
- FLEXUS™
- Helifix® Interspinous Spacer System
- In-Space
- NL-Prow™ Interspinous Spacer
- Stenofix
- Vertiflex™ Superior® Interspinous Spacer System
- Wallis System®

### MEDICARE AND MEDICAL NECESSITY

Only medically reasonable and necessary services or items which treat illness or injury are eligible for Medicare coverage, as outlined in *Title XVIII of the Social Security Act, §1862(a)(1)(A)*. No MAC currently has a local coverage determination (LCD) or article (LCA) to address Interspinous Process Decompression (IPD), which may also be referred to as spinal stabilization devices or interspinous spacers. First Coast Service Options **used to** have a relevant LCD and companion LCA (L34006/A57123), but these were retired in April 2020. However, this MAC is not the MAC assigned jurisdiction over the health plan service area, so this LCD and LCA have never been used by this plan. The MAC for the health plan service area – Noridian – does not have an active LCD or LCA which addresses these services. Noridian had an LCA for the X-STOP® IPD device (A46408), but this LCA was retired in 2012, followed shortly by the withdrawal of FDA approval of the X-STOP device in 2015.

#### Absence of Medicare Coverage Policy

“MA organizations may create publicly accessible internal coverage criteria that are based on current evidence in widely used treatment guidelines or clinical literature when coverage criteria are not fully established in applicable Medicare statutes, regulations, NCDs or LCDs. Current, widely-used treatment guidelines are those developed by organizations representing clinical medical specialties, and refers to guidelines for the treatment of specific diseases or conditions. Acceptable clinical literature includes large, randomized controlled trials or prospective cohort studies with clear results, published in a peer-reviewed journal, and specifically designed to answer the relevant clinical question, or large systematic reviews or meta-analyses summarizing the literature of the specific clinical question.” (*§ 422.101(b)(6) and Medicare Managed Care Manual, Ch. 4, §90.5*)

MA organizations (MAOs) make medical necessity determinations based on coverage and benefit criteria, current standards of care, the member’s unique personal medical history (e.g., diagnoses, conditions, functional status, co-morbidities, etc.), physician recommendations, and clinical notes, as well as involvement of a plan medical director, where appropriate. (*§ 422.101(c)(1)*)

The Plan’s Medicare policy for *PHA Medicare Medical Policy Development and Application* ([MP50](#)) provides details regarding Medicare’s definition of medical necessity and the hierarchy of Medicare references and resources during the development of medical policies, as well as the Plan’s use of evidence-based processes for policy development.

Since there are not fully established coverage criteria for dynamic stabilization devices and interspinous spacers available in applicable Medicare statutes, regulations, NCDs or LCDs, then Company medical policy criteria will be applied. See the [Medicare Coverage Criteria](#) table above for more information regarding the use of internal coverage criteria when Medicare coverage criteria are not fully established.

Following an evidence review, it is concluded that the evidence does not support the safety and efficacy of dynamic stabilization devices and interspinous spacers. All systematic reviews to date note a paucity of long-term evidence from high-quality trials. The literature largely comprises small, uncontrolled studies with short-term follow-up. Moreover, no evidence-based clinical practice guidelines recommend dynamic stabilization devices or interspinous spacers in lieu of, or in addition to, interbody fusion and/or decompression fusion for the treatment of lumbar spinal stenosis. While one guideline recommends interspinous spacers in addition to interbody fusion and/or decompression fusion for the treatment of lumbar spinal stenosis, the evidence used to support this recommendation suffers from the following limitations: heterogenous patient populations; nonrandomized design; high potential for patient selection bias; relatively limited follow-up in most studies; small sample size; absence of power analyses; inadequate blinding; potential for reporting bias, including censored data and missing data for some outcomes and time point.

## REGULATORY STATUS

### U.S. FOOD & DRUG ADMINISTRATION (FDA)

While clearance by the Food and Drug Administration (FDA) is a prerequisite for Medicare coverage, the 510(k) premarket clearance process does not in itself establish medical necessity. Medicare payment policy is determined by the interaction of numerous requirements, including but not limited to, the

availability of a Medicare benefit category and other statutory requirements, coding and pricing guidelines, as well as national and local coverage determinations and clinical evidence.

The following dynamic stabilization devices and interspinous spacers have received FDA clearance:

- Aspen Spinous Fixation System
- DSS Stabilization System<sup>3</sup>
- Dynesys<sup>®4</sup>
- Isobar Spinal System<sup>5</sup>
- Coflex<sup>®</sup> Interlaminar Stabilization Device<sup>6</sup>
- Vertiflex<sup>™</sup> Superior Interspinous Spacer System<sup>7</sup>

**Note:** The Vertiflex<sup>™</sup> Superior is one of only two interspinous spacer or spinous process plates with full FDA-approval. Following worldwide recalls, the formerly approved X-STOP devices had FDA-approval formally withdrawn in 2015.<sup>8</sup>

In order to be considered for coverage under Medicare, devices must be either FDA- or Institutional Review Board (IRB)-approved. Therefore, any device that has **not** received FDA-approval would be considered not medically necessary.<sup>9</sup>

## BILLING GUIDELINES AND CODING

### GENERAL

The following codes do not apply to minimally invasive dynamic stabilization procedures of the spine and should **not** be used to bill for these services: 22533, 22534, 22558, 22585, 22586, 22612, 22614, 22630, 22632, 22633, 22634, 22800, 22802, 22804, 22808, 22810, 22812, 22840, 22841, 22842, 22843, 22844, 22845, 22846, 22847, 22853, 22854, 22859.

CODES*		
<b>CPT</b>	22867	Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; single level
	22868	Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; second level (List separately in addition to code for primary procedure)
	22869	Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; single level
	22870	Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; second level (List separately in addition to code for primary procedure)
	22899	Unlisted procedure, spine
	64999	Unlisted procedure, nervous system
<b>HCPCS</b>	C1821	Interspinous process distraction device (implantable)
	L8699	Prosthetic implant, not otherwise specified

#### \*Coding Notes:

- The code list above is provided as a courtesy and may not be all-inclusive. Inclusion or omission of a code from this policy neither implies nor guarantees reimbursement or coverage. Some codes may not require routine review for medical necessity, but they are subject to provider contracts, as well as member benefits, eligibility and potential utilization audit. According to Medicare, “presence of a payment amount in the MPFS and the Medicare physician fee schedule database (MPFSDB) does not imply that CMS has determined that the service may be covered by Medicare.” The issuance of a CPT or HCPCS code or the provision of a payment or fee amount by Medicare does **not** make a procedure medically reasonable or necessary or a covered benefit by Medicare. (*Medicare Claims Processing Manual, Chapter 23 - Fee Schedule Administration and Coding Requirements, §30 - Services Paid Under the Medicare Physician’s Fee Schedule, A. Physician’s Services*)
- All unlisted codes are reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is submitted for non-covered services addressed in this policy then it will be **denied as not covered**. If an unlisted code is submitted for potentially covered services addressed in this policy, to avoid post-service denial, **prior authorization is recommended**.
- **See the non-covered and prior authorization lists on the Company [Medical Policy, Reimbursement Policy, Pharmacy Policy and Provider Information website](#) for additional information.**
- HCPCS/CPT code(s) may be subject to National Correct Coding Initiative (NCCI) procedure-to-procedure (PTP) bundling edits and daily maximum edits known as “medically unlikely edits” (MUEs) published by the Centers for Medicare and Medicaid Services (CMS). This policy does not take precedence over NCCI edits or MUEs. Please refer to the CMS website for coding guidelines and applicable code combinations.

## REFERENCES

1. Centers for Medicare and Medicaid Services (CMS). Approved IDE Studies. Last Modified: 9/6/2023. <https://www.cms.gov/Medicare/Coverage/IDE/Approved-IDE-Studies>. Accessed 4/10/2026.
2. U.S. Food and Drug Administration (FDA). Biomet Fusion System. Decision Date 2/28/3017. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmnmn.cfm?ID=K163543>. Accessed 4/10/2026.
3. FDA. DSS Stabilization System. Decision Date 7/2/2010. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmnmn.cfm?ID=K101083>. Accessed 4/10/2026.
4. FDA. Dynesys Spinal System. Decision Date, 3/5/2004. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmnmn.cfm?ID=K031511>. Accessed 4/10/2026.
5. FDA. Isobar Spinal System. Decision Date, 1/15/2002. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmnmn.cfm?ID=K013447>. Accessed 4/10/2026.
6. FDA. Coflex-F Implant System. Decision Date, 2/13/2012. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmnmn.cfm?ID=K112595>. Accessed 4/10/2026.
7. FDA. Superior Interspinous Spacer. Decision Date, 5/20/2015. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140004>. Accessed 4/10/2026.
8. FDA. Premarket Approval (PMA). Device: X Stop Interspinous Process Decompression System Withdrawl date: 04/30/2015. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P040001>. Accessed 4/10/2026.
9. Medicare Benefit Policy Manual, Chapter 14 – Medical Devices, §10 – Coverage of Medical Devices. Updated: 1/5/2015. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/bp102c14.pdf>. Accessed 4/10/2026.

## **POLICY REVISION HISTORY**

<b>DATE</b>	<b>REVISION SUMMARY</b>
7/2023	New Medicare Advantage medical policy
6/2024	Annual review, no criteria change
6/2025	Annual review, no criteria change
6/2026	Annual review, no criteria change